Fig. 4

Ricolinostat promoted megakaryocytic specification of CD34⁺CD41a⁻ cells. A Schematic diagram illustrating that CD34⁺CD41a⁻ cells were sorted from expanded HSPCs and then treated with Ricolinostat for 7 days. B Flow cytometry analysis of CD34, CD41a, and CD61 expression in Ricolinostat-treated CD34⁺CD41a⁻ cells. C Percentage of CD34⁺CD41a⁺ cells in Ricolinostat-treated CD34⁺CD41a⁻ cells. D Absolute counts of CD34⁺CD41a⁺ cells were calculated and normalized to the initial sorted CD34⁺CD41a⁻ cells. E Percentage of CD41a⁺CD61⁺ cells in Ricolinostat-treated CD34⁺CD41a⁻ cells. F Absolute counts of CD41a⁺CD61⁺ cells were calculated and normalized to the initial sorted CD34⁺CD41a⁻ cells. G qRT-PCR analysis of some MkP-related genes in Ricolinostat-treated and -untreated CD34⁺CD41a⁻ cells. Results are expressed as the mean ± SEM from three independent experiments. Unpaired Student’s t-test, *p < 0.05; **p < 0.01